Actively Recruiting

Phase 2
Age: 18Years - 64Years
All Genders
Healthy Volunteers
NCT07379580

A Randomized Clinical Trial Investigating the Safety, Reactogenicity, and Immunogenicity After Immunization With an mRNA-based Mpox Vaccine Candidate in Africa

Led by BioNTech SE · Updated on 2026-03-04

310

Participants Needed

6

Research Sites

66 weeks

Total Duration

On this page

Sponsors

B

BioNTech SE

Lead Sponsor

C

Coalition for Epidemic Preparedness Innovations

Collaborating Sponsor

AI-Summary

What this Trial Is About

This is a randomized, double-blind, placebo-controlled study which aims to assess the safety, reactogenicity, and immunogenicity after one and two doses of BNT166a or placebo in healthy participants.

CONDITIONS

Official Title

A Randomized Clinical Trial Investigating the Safety, Reactogenicity, and Immunogenicity After Immunization With an mRNA-based Mpox Vaccine Candidate in Africa

Who Can Participate

Age: 18Years - 64Years
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Male or female individuals aged 18 years or older at the time of consent
  • Cohort 1: Age 18 to 45 years and Orthopoxvirus-naïve (no history of smallpox or mpox vaccination or infection)
  • Cohort 2: Age 18 to 64 years and Orthopoxvirus-experienced (evidence of mpox or smallpox vaccination or infection at least 2 years prior)
Not Eligible

You will not qualify if you...

  • Recent exposure to mpox within 28 days or mpox vaccination/infection within 2 years prior to consent
  • Contraindications or warnings for mRNA COVID-19 vaccines as specified in product information
  • History of allergies or intolerance to study treatments or their ingredients
  • Current or past cardiovascular diseases such as myocarditis, pericarditis, myocardial infarction, heart failure, cardiomyopathy, or significant arrhythmias
  • Known bleeding disorders or conditions that contraindicate intramuscular injection
  • Body mass index less than 18.5 or greater than 35 kg/m²
  • Other protocol-defined criteria apply

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 6 locations

1

University of Kinshasa UNIKIN

Kinshasa, Democratic Republic of the Congo, 01306

Not Yet Recruiting

2

Institute National de Recherche Biomedicale

Kinshasa, Democratic Republic of the Congo, 5345

Not Yet Recruiting

3

TASK Applied Science

Cape Town, South Africa, 7405

Not Yet Recruiting

4

TREAD Research Pty Ltd

Cape Town, South Africa, 7530

Actively Recruiting

5

Desmond Tutu Health Foundation Masiphumelele Clinic

Cape Town, South Africa, 7975

Not Yet Recruiting

6

Perinatal HIV Research Unit

Johannesburg, South Africa, 1864

Actively Recruiting

Loading map...

Research Team

B

BioNTech clinical trials patient information

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

PREVENTION

Number of Arms

6

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here